.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,246,934

« Back to Dashboard

Details for Patent: 8,246,934

Title:Respiratory dispersion for metered dose inhalers comprising perforated microstructures
Abstract: A respiratory dispersion for pulmonary delivery comprises one or more bioactive agents, a suspension medium, and a plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 .mu.m. The suspension medium comprises at least one propellant and permeates the perforated microstructures.
Inventor(s): Weers; Jeffry G. (Belmont, CA), Schutt; Ernest G. (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Tarara; Thomas E. (Burlingame, CA), Kabalnov; Alexey (Corvallis, OR)
Assignee: Novartis AG (Basel, CH)
Filing Date:Sep 03, 2010
Application Number:12/875,966
Claims:1. A respiratory dispersion for pulmonary delivery, the respiratory dispersion comprising: one or more bioactive agents; a suspension medium; a plurality of perforated microstructures having a mean aerodynamic diameter of less than 5 .mu.m, wherein said suspension medium comprises at least one propellant and permeates said perforated microstructures.

2. The respiratory dispersion of claim 1, wherein said propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoro-n-propane, perfluoroethane, monochlorodifluoromethane, 1,1-difluoroethane and combinations thereof.

3. The respiratory dispersion of claim 1 wherein said perforated microstructures comprise a surfactant.

4. The respiratory dispersion of claim 3 wherein said surfactant is selected from the group consisting of phospholipids, nonionic detergents, nonionic block copolymers, ionic surfactants, biocompatible fluorinated surfactants and combinations thereof.

5. The respiratory dispersion of claim 3 wherein said surfactant comprises a phospholipid.

6. The respiratory dispersion of claim 5 wherein said phospholipid is selected from the group consisting of dilauroylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, disteroylphosphatidyl-choline behenoylphosphatidylcholine, arachidoylphosphatidylcholine and combinations thereof.

7. The respiratory dispersion of claim 1 wherein the mean geometric diameter of the perforated microstructures is between 1 and 5 .mu.m.

8. The respiratory dispersion of claim 1 wherein said bioactive agent is selected from the group consisting of antiallergics, bronchodilators, pulmonary lung surfactants, analgesics, antibiotics, antiinfectives, leukotriene inhibitors or antagonists, antihistamine, antiinflammatories, antineoplastics, antocholinergics, anesthetics, anti-tuberculars, imaging agents, cardiovascular agents, enzymes, steroids, genetic material, viral vectors, antisense agents, proteins, peptides, and combinations thereof.

9. A respiratory dispersion of claim 1 wherein the bioactive agent comprises a bronchodilator.

10. A respiratory dispersion of claim 9 wherein said bronchodilator is selected from ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, albuterol, salmeterol, and terbutaline.

11. A respiratory dispersion of claim 1 wherein the bioactive agent comprises an anti-inflammatory agent.

12. A respiratory dispersion of claim 11 wherein the anti-inflammatory agent comprises an anti-inflammatory steroid.

13. A respiratory dispersion of claim 12 wherein the anti-inflammatory agent comprises one or more of fluticasone, beclomethasone, flunisolide, budesonide, tripedane, cortisone, prednisone, prednisolone, dexamethoasone, betamethasone or triamcinalone.

14. A respiratory dispersion of claim 1 comprising beclomethasone.

15. A respiratory dispersion of claim 1 comprising formoterol.

16. A respiratory dispersion of claim 1 comprising beclomethasone diproprionate and formoterol.

17. A respiratory dispersion of claim 1 wherein the bioactive agent comprises an anti-cholinergic agent.

18. A respiratory dispersion of claim 17 where the anti-cholinergic agent comprises one or more of ipratropium, atropine, or oxitropium.

19. A respiratory dispersion of claim 9 wherein said bronchodilator is salbutamol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc